Peptides DB
Research-centric peptide and protocol reference hub
Study 13 of 13Tirzepatide literatureVirulence · Observational2026

Genomic analyses identify nosocomial transmission of ST23 carbapenem-resistant hypervirulent <i>Klebsiella pneumoniae</i> mediated by a conjugative IncFII<sub>K2</sub> NDM-1 plasmid.

This study highlights the need for enhanced surveillance of plasmid transmission in Klebsiella pneumoniae to mitigate public health risks.

Read at VirulenceAdd to compare

Where it sits

this study against the rest of the tirzepatide corpus
1
Preclinical
10
Observational · this one
0
Open-label
0
Randomised
2
Reviews

Summary and findings

This study identified and characterized ST23 carbapenem-resistant hypervirulent Klebsiella pneumoniae bloodstream isolates from 2019-2023. Among 1069 CRKP bloodstream isolates, four ST23-K1 strains (0.37%) were detected, with clinical outcomes showing that three patients recovered after antibiotic therapy. The study emphasizes the importance of plasmid-focused surveillance due to the identified resistance mechanisms and transmission dynamics.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
0.37% ST23-K1 strains detected among 1069 CRKP bloodstream isolates.n=10692026

Abstract

The authors’ words, as Virulence supplied them

The World Health Organization has identified ST23 carbapenem-resistant hypervirulent <i>Klebsiella pneumoniae</i> (CR-hvKP) as a critical public health threat. Through China's national surveillance system (BRICS), we identified and characterized ST23 CR-hvKP bloodstream isolates from 2019-2023. Among 1069 CRKP bloodstream isolates, four ST23-K1 strains (0.37%) were detected across two hospitals, including a nosocomial transmission pair (differing by only 2 core SNPs). Clinical outcomes revealed that three of the four patients achieved recovery following appropriate antibiotic therapy, with one mortality case attributed to underlying comorbidities. All four ST23 isolates demonstrated resistance to multiple antibiotics, indicating a pattern of multidrug resistance. Genomic analysis uncovered diverse resistance mechanisms: the nosocomial transmission pair possessed conjugative IncFII<sub>K2</sub> NDM-1 plasmids, while the others harbored conjugative IncFII<sub>K34</sub> KPC-2 plasmids, which exhibited reduced carbapenem resistance attributed to the downregulation of <i>bla</i><sub>KPC-2</sub> expression. Conjugation assays revealed high transferability (10<sup>-5</sup> for IncFII<sub>K2</sub> NDM-1; 10<sup>-4</sup> for IncFII<sub>K34</sub> KPC-2). Whole-plasmid comparative genomics analysis suggested that the IncFII<sub>K2</sub> NDM-1 plasmids shared > 99% identity with historical IncFII<sub>K2</sub> plasmid backbones from Chinese <i>K. pneumoniae</i> isolates (2014-2022), suggesting local evolution. Notably, only 4.4% (26/590) of global IncFII<sub>K2</sub> plasmids carried <i>bla</i><sub>NDM-1</sub> and all IncFII<sub>K2</sub> NDM-1 plasmids maintain conjugative potential. All strains harbored conserved virulence plasmids and maintained hypervirulence, as indicated by a mouse infection model, with the exception of one strain that exhibited <i>cps</i> mutations. This study reports the first genomic evidence of a high-frequency conjugative IncFII<sub>K2</sub> NDM-1 plasmid in a hospital-transmitted ST23 CR-hvKP clone, highlighting the need for plasmid-focused surveillance to control this potential threat.

Background

The study addresses the public health threat posed by ST23 carbapenem-resistant hypervirulent Klebsiella pneumoniae, which has been recognized by the World Health Organization. Prior knowledge indicated that this pathogen exhibits multidrug resistance and poses significant risks in healthcare settings. This research is critical as it provides genomic insights into the transmission dynamics and resistance mechanisms of this strain.

Methods

The study utilized China's national surveillance system (BRICS) to identify and characterize ST23 CR-hvKP bloodstream isolates from 2019 to 2023. A total of 1069 CRKP bloodstream isolates were analyzed, with a focus on four identified ST23-K1 strains. The study employed genomic analysis and conjugation assays to assess resistance mechanisms and plasmid transferability.

Results

Among 1069 CRKP bloodstream isolates, four ST23-K1 strains (0.37%) were detected. Three of the four patients achieved recovery following appropriate antibiotic therapy, while one case resulted in mortality due to underlying comorbidities. The conjugation assays indicated high transferability rates of the plasmids, with 10^-5 for IncFII_K2 NDM-1 and 10^-4 for IncFII_K34 KPC-2.

Interpretation

The findings suggest a concerning trend in the transmission of hypervirulent strains of Klebsiella pneumoniae, particularly with the identified plasmids. While the study presents statistically significant data regarding plasmid transferability, the clinical significance of these findings remains uncertain due to the small sample size and lack of broader clinical context. The reliance on genomic analysis may limit the applicability of results to real-world clinical scenarios.

Key findings

  • 0.37% ST23-K1 strains detected among 1069 CRKP bloodstream isolates.
  • Three of the four patients achieved recovery following appropriate antibiotic therapy.
  • One mortality case attributed to underlying comorbidities.
  • Conjugation assays revealed high transferability (10^-5 for IncFII_K2 NDM-1; 10^-4 for IncFII_K34 KPC-2).
  • > 99% identity with historical IncFII_K2 plasmid backbones from Chinese K. pneumoniae isolates (2014-2022).
  • Only 4.4% (26/590) of global IncFII_K2 plasmids carried bla_NDM-1.

Limitations

  • small n=4 for ST23 strains identified
  • reliance on genomic analysis without clinical trials
  • observational study design limits causal inference
  • short follow-up period for clinical outcomes

Elsewhere in the Tirzepatide corpus

BSerious acute biliary reporting with glucagon-like peptide-1-based therapies versus sodium-glucose cotransporter-2 inhibitors in type 2 diabetesbiorxiv-preprint · 2026 · 1.36 reporting odds ratio (95% CI 1.06-1.75; P = 0.013)HumanBReal-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.Obesity pillars · 2026 · 90% (n=45/48) of PwO reported likelihood to recommend tirzepatide.HumanBChanges in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study.europepmc · 2026 · Weight loss of approximately 5.5 kg, n=28, P<0.001.HumanBAnnual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK.europepmc · 2026 · n=500 · Cost per patient achieving HbA1c ≤6.5%, weight loss ≥15%, and no hypoglycemia was GBP 5,650 lower with tirzepatide 5 mg compared to semaglutide 1 mg.HumanDEnhancing economic modelling in obesity: integrating novel type 2 diabetes progression &amp; obstructive sleep apnea remission - a UK case study.europepmc · 2026 · ICERs: £8,327-£10,157 per QALY gained.CTirzepatide Attenuates Diabetes-Associated Testicular Inflammation and Sperm DNA Fragmentation in Obese Diabetic Mice: Potential Pleiotropic Effects Beyond Glycemic Controlbiorxiv-preprint · 2026 · n=30 · 1.00 nmol/kg/day tirzepatide reduced HbA1c levels, p<0.001.Animal